September 16, 2024 version of the negotiating text for a WHO pandemic agreement
Author: James Love
KEI comment to USPTO on the need for a statutory experimental use exception for patents
The USPTO has a request for comment on the need for a statutory experimental use exception for patents. (89 FR 53963). The USPTO uploads the comments to Regulations.Gov, docket PTO-C-2024-0023. KEI filed comments on September 10, 2024: KEI-Experimental-use-exception-10Sept2024 September 10,… Continue Reading
KEI letter to the NIH regarding need for better reporting on the utilization of licensed inventions and access in developing countries
The PDF version of the letter has all tables and footnotes: KEI-NIH-28Aug2028 August 28, 2024 Abby Rives, JD Division Director Technology Transfer and Innovation Policy National Institutes for Health Vladimir Knezevic, MD Senior Advisor for Commercial Evaluation Technology Advancement Office… Continue Reading
NIH announces new policy to deal with access to NIH licensed inventions
In a notice to the federal register, the NIH is announcing a new policy to address issues of access and equity in the licensing of NIH patented inventions. (The Federal Register notice is here. Secretary Becerra announcement is here). The… Continue Reading
Letter to Anne Yu, Director for Global Pandemic Preparedness, NSC, on negotiations for WHO pandemic agreement
This was sent via email today. Jamie ————— May 1, 2024 Anne Yu Director for Global Pandemic Preparedness Development, Global Health and Humanitarian Response, National Security Council Staff, Executive Office of the President Dear Anne Yu, I’m guessing you are… Continue Reading
The WHO Pandemic agreement, language on mutually agreed terms for technology transfer, and claims under investor-state dispute resolution (ISDS)
This is an annex to the document: KEI comments on six references to “mutually agreed terms” in the WHO pandemic agreement negotiating text: A/INB/9/3 Rev.1, 22 April 2024, which is available as a PDF here: KEI.MutuallyAgreedTerms.A_INB_9_3Rev1.22April2024draft Annex on Investor-State Dispute… Continue Reading
KEI comments on six references to “mutually agreed terms” in the WHO pandemic agreement negotiating text: A/INB/9/3 Rev.1, 22 April 2024
PDF version is available here: KEI.MutuallyAgreedTerms.A_INB_9_3Rev1.22April2024draft KEI comments on six references to “mutually agreed terms” in the WHO pandemic agreement negotiating text: A/INB/9/3 Rev.1, 22 April 2024 James Love Knowledge Ecology International April 28, 2024, revised April 29, 2024 Introduction… Continue Reading
April 22, 2024 WHO Pandemic agreement negotiating text
A_inb9_3Rev1-en22april2024 There are seven references to “mutually agreed” terms in the text relating to intellectual property and knowledge sharing, and some of these can and will be used to intimidate developing countries from using mandatory measures. The United States used… Continue Reading
Colombia issues a compulsory license on patents for the HIV drug Dolutegravir
Request for CMS to provide a Bayh-Dole Section 202 license and a 28 USC 1498 authorization and consent to use three patents listed in the FDA Orange Book for the cancer drug enzalutamide
Letter from KEI, UACT and UAEM to Chiquita White Brooks-Lasure, Administrator of the Office of the Administrator, Centers for Medicare and Medicaid Services, at HHS, asking that CMS to provide a Bayh-Dole Section 202 license and a 28 USC 1498… Continue Reading